Monoamine transporters as continuing targets for drug discovery in depression

Drug Discovery Today: Therapeutic Strategies

Volumn 1, Issue 1, 2004, Pages 111-116

  Klint, Thorsten ^a   Weikop, Pia ^a  

^a NEUROSEARCH A S   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; CARRIER PROTEIN; CITALOPRAM; DESIPRAMINE; DULOXETINE; FLUOXETINE; GABOXADOL; IRINDALONE; KETANSERIN; METHYLPHENIDATE; MIRTAZAPINE; MIXED SEROTONIN NORADRENALIN UPTAKE INHIBITOR; MONOAMINE; MONOAMINE OXIDASE INHIBITOR; NEFAZODONE; NOMIFENSINE; NORADRENALIN UPTAKE INHIBITOR; OLANZAPINE; PAROXETINE; PERGOLIDE; PINDOLOL; PRAMIPEXOLE; SEROTONIN 1A ANTAGONIST; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; VENLAFAXINE;

ARTICLE; CARDIOVASCULAR SYMPTOM; CLINICAL TRIAL; DEPRESSION; DOSE RESPONSE; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; DRUG RESPONSE; DRUG SAFETY; DRUG SELECTIVITY; DRUG TARGETING; DRUG TOLERABILITY; HUMAN; NAUSEA; NONHUMAN; RECEPTOR OCCUPANCY; REMISSION; SEXUAL DYSFUNCTION;

EID: 13444271953     PISSN: 17406773     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ddstr.2004.08.014     Document Type: Review

References (40)

1. D. Smith et al. Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: A meta-analysis Br. J. Psychiatry 180 2002 396-404
2. H. Lavretsky et al. Combined treatment with methylphenidate and citalopram for accelerated response in the elderly: An open trial J. Clin. Psychiatry 64 2003 1410-1414
3. R.W. Lam et al. Citalopram and bupropion-SR: Combining versus switching in patients with treatment-resistant depression J. Clin. Psychiatry 65 2004 337-340
4. N.D. Volkow et al. Role of dopamine in the therapeutic and reinforcing effects of methylphenidate in humans: Results from imaging studies Eur. Neuropsychopharmacol. 12 2002 557-566
5. S.M. Learned-Coughlin et al. In vivo activity of bupropion at the human dopamine transporter as measured by positron emission tomography Biol. Psychiatry 54 2003 800-805
6. J.H. Meyer et al. Occupancy of serotonin transporters by paroxetine and citalopram during treatment of depression: A [(11)C]DASB PET imaging study Am. J. Psychiatry 158 2001 1843-1849
7. J.F. Cryan et al. Norepinephrine-deficient mice lack responses to antidepressant drugs, including selective serotonin reuptake inhibitors Proc. Natl. Acad. Sci. USA 101 2004 8186-8191 (Epub. 17 May 2004)
8. S. Mace D. Taylor Selective serotonin reuptake inhibitors: A review of efficacy and tolerability in depression Expert Opin. Pharmacother. 1 2000 917-933
9. C.E. Nieuwstraten L.R. Dolovich Bupropion versus selective serotonin-reuptake inhibitors for treatment of depression Ann. Pharmacother. 35 2001 1608-1613
10. C.C. Coleman et al. Sexual dysfunction associated with the treatment of depression: A placebo-controlled comparison of bupropion sustained release and sertraline treatment Ann. Clin. Psychiatry 11 1999 205-215
11. W. Zhang et al. Synergistic effects of olanzapine and other antipsychotic agents in combination with fluoxetine on norepinephrine and dopamine release in rat prefrontal cortex Neuropsychopharmacology 23 2000 250-262
12. M.D. Wood et al. Therapeutic potential of serotonin antagonists in depressive disorders Expert Opin. Investig. Drugs 11 2002 457-467
13. F.P. Bymaster et al. New approaches to developing antidepressants by enhancing monoaminergic neurotransmission Expert Opin. Investig. 12 2003 531-543
14. F. Artigas et al. How does pindolol improve antidepressant action? Trends Pharmacol. Sci. 22 2001 224-228
15. P. Blier The pharmacology of putative early-onset antidepressant strategies Eur. Neuropsychopharmacol. 13 2003 57-66
16. M. Fava Augmentation and combination strategies in treatment-resistant depression J. Clin. Psychiatry 62 Suppl. 18 2001 4-11
17. D. Martinez et al. Pindolol augmentation of antidepressant treatment: recent contributions from brain imaging studies Biol. Psychiatry 48 2000 844-853
18. B.L. Jacobs et al. Adult brain neurogenesis and psychiatry: A novel theory of depression Mol. Psychiatry 5 2000 262-269
19. P.B. Hedlund et al. No hypothermic response to serotonin in 5-HT7 receptor knockout mice Proc. Natl. Acad. Sci. USA 100 2003 1375-1380 (Epub.)
20. J.P. Anthony et al. Antidepressant-induced regulation of 5-HT(1b) mRNA in rat dorsal raphe nucleus reverses rapidly after drug discontinuation J. Neurosci. Res. 61 2000 82-87
21. P. Rasanen et al. Mitchell B. Balter Award - 1998. Pindolol and major affective disorders: A three-year follow-up study of 30,485 patients J. Clin. Psychopharmacol. 19 1999 297-302
22. Z.A. Hughes L.A. Dawson Differential autoreceptor control of extracellular 5-HT in guinea pig and rat: Species and regional differences Psychopharmacology (Berl.) 172 2004 87-93
23. A. Gobert et al. Serotonin(2C) receptors tonically suppress the activity of mesocortical dopaminergic and adrenergic, but not serotonergic, pathways: A combined dialysis and electrophysiological analysis in the rat Synapse 36 2000 205-221
24. R.C. Shelton Intracellular mechanisms of antidepressant drug action Harv. Rev. Psychiatry 8 2000 161-174
25. M. Maes et al. Pindolol and mianserin augment the antidepressant activity of fluoxetine in hospitalized major depressed patients, including those with treatment resistance J. Clin. Psychopharmacol. 19 1999 177-182
26. K.E. Wortley et al. Comparison of changes in the extracellular concentration of noradrenaline in rat frontal cortex induced by sibutramine or d-amphetamine: Modulation by alpha2-adrenoceptors Br. J. Pharmacol. 127 1999 1860-1866
27. A. Bouckoms L. Mangini Pergolide: An antidepressant adjuvant for mood disorders? Psychopharmacol. Bull. 29 1993 207-211
28. N. Bonhomme E. Esposito Involvement of serotonin and dopamine in the mechanism of action of novel antidepressant drugs: A review J. Clin. Psychopharmacol. 18 1998 447-454
29. G. Tanda et al. Chronic desipramine and fluoxetine differentially affect extracellular dopamine in the rat prefrontal cortex Psychopharmacology (Berl.) 127 1996 83-87
30. T. Kihara M. Ikeda Effects of duloxetine, a new serotonin and norepinephrine uptake inhibitor, on extracellular monoamine levels in rat frontal cortex J. Pharmacol. Exp. Ther. 272 1995 177-183
31. P. Weikop et al. The role of 1- and 2-adrenoreceptors in augmentation of venlafaxine-induced elevation of extracellular serotonin, noradrenaline and dopamine levels in the rat prefrontal cortex and hippocampus J. Psychopharmacol. 18 2004 357-365
32. M.D. Waldinger et al. Antidepressants and ejaculation: A double-blind, randomized, fixed-dose study with mirtazapine and paroxetine J. Clin. Psychopharmacol. 23 2003 467-470
33. M.D. Waldinger et al. Antidepressants and ejaculation: A double-blind, randomized, placebo-controlled, fixed-dose study with paroxetine, sertraline, and nefazodone J. Clin. Psychopharmacol. 21 2001 293-297
34. J.M. Ferguson SSRI antidepressant medications: Adverse effects and tolerability Prim. Care Companion J. Clin. Psychiatry 3 2001 22-27
35. T. Klint et al. The selective 5-HT2 receptor antagonist amperozide attenuates 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane-induced inhibition of male rat sexual behavior Eur. J. Pharmacol. 212 1992 241-246
36. B. Costall R.J. Naylor 5-HT3 receptors Curr. Drug Target CNS Neurol. Disord. 3 2004 27-37
37. Y.I. Sheline et al. Hippocampal atrophy in recurrent major depression Proc. Natl. Acad. Sci. USA 93 1996 3908-3913
38. B. Chen et al. Increased hippocampal BDNF immunoreactivity in subjects treated with antidepressant medication Biol. Psychiatry 50 2001 260-265
39. P.S. Eriksson et al. Neurogenesis in the adult human hippocampus Nat. Med. 4 1998 1313-1317
40. D.C. Lie et al. Neurogenesis in the adult brain: New strategies for central nervous system diseases Annu. Rev. Pharmacol. Toxicol. 44 2004 399-421